Oleoylethanolamide

Oleoylethanolamide (OEA) is a molecule produced in the body, usually found in the intestines. It is responsible for the feeling of satiety after meals. Further research is needed to determine if oral supplementation of OEA provides benefits for weight loss.

This page features 47 unique references to scientific papers.


Research analysis by and verified by the Examine.com Research Team. Last updated on Apr 29, 2017.

Summary of Oleoylethanolamide

Primary Information, Benefits, Effects, and Important Facts

In Progress


This page on Oleoylethanolamide is currently marked as in-progress. We are still compiling research.



Oleoylethanolamide (OEA) is a molecule produced in the body, usually found in the intestines. It is responsible for the feeling of satiety following meals.

OEA is sometimes included in fat burning supplement stacks. There is currently no human evidence that suggests oral supplementation of OEA is able to burn fat.

OEA acts on a receptor called Peroxisome Proliferator-Activated Receptor Alpha (PPARα). When this receptor is activated in the intestines of rats, the animals consume less food. Research on rats shows that both injections and oral intake of OEA causes a reliable reduction in the amount of food eaten.

Limited human evidence suggests that OEA may be able to aid fat loss by acting on PPARα. When this receptor is activated in fat tissue, energy expenditure increases. Further evidence is needed before oral supplementation of OEA can be recommended for weight loss.

How to Take

Recommended dosage, active amounts, other details

Research on rats has observed effects at a daily dose of 10mg/kg of bodyweight. This is roughly equivalent to the following human dosages:

  • 100mg for a 150lb person

  • 145mg for a 200lb person

  • 180mg for a 250lb person

Scientific Research

Table of Contents:

  1. 1 Sources and Structure
    1. 1.1 Sources
    2. 1.2 Biological Significance
    3. 1.3 Formulations and Variants
  2. 2 Molecular Targets
    1. 2.1 PPARs
    2. 2.2 GPRs
  3. 3 Pharmacology
    1. 3.1 Absorption
  4. 4 Neurology
    1. 4.1 Adrenergic Neurotranmission
    2. 4.2 Serotonergic Neurotransmission
    3. 4.3 Dopaminergic Neurotransmission
    4. 4.4 Miscellaneous Mechanisms
    5. 4.5 Appetite and Food Intake
    6. 4.6 Anxiety
    7. 4.7 Depression
  5. 5 Obesity and Fat Mass
    1. 5.1 Adipokines
    2. 5.2 Lipolysis
    3. 5.3 Weight
  6. 6 Interactions with Hormones
    1. 6.1 Ghrelin
    2. 6.2 Peptide YY
  7. 7 Peripheral Organ Systems
    1. 7.1 Pancreas
  8. 8 Interactions with Medical Conditions
    1. 8.1 Parkinson's Disease


1Sources and Structure

1.1. Sources

Oleoylethanolamide (OEA) is an endogenous regulator of appetite which suppresses food intake.[3] It is in the class of molecules known as acylethanolamides, which are ethanolamide molecules based off of fatty acids and usually related to the arachidonic acid derivative and cannabinoid known as anandamide.[4] Also in this category of molecules is the endogenous sleep regulator oleamide, which is structurally similar to anandamide and OEA.

1.2. Biological Significance

OEA is thought to be an endogenous regulator of satiety. Basal concentrations of OEA in the intestines (where it initially acts) without supplementation are in the range of 300nM during daylight hours in rats when they are satiated, and this concentration is enough to fully saturate the receptor it acts upon (PPARα).[5] At night time, when rats tend to increase food intake, its concentrations drop to levels that no longer saturate the receptor.[5]

It is synthesized in vivo from fatty acids from cell membranes, and is released when feeding occurs.[6]

OEA appears to be present in the intestinal tract and its concentration in tissue seems to be associated with the level of satiety in rats. Its secretion is increased when food is ingested, suggesting a link between OEA and feeding-induced satiety.

OEA can be synthesized in neurons in rats.[7]

OEA is eliminated by enzymatic hydrolysis similar to most acylethanolamides, where enzymes known as amidases cleave OEA into a fatty acid component (in the case of OEA, oleic acid) which can then be used in phospholipid production, and ethanolamine which can be shunted into phosphatidylethanolamine production.[8][9]

1.3. Formulations and Variants

An N-acyl-phosphatidylethanolamine (NAPE) is a phosphatidylethanolamine molecule with the three standard glycerol binding spots containing fatty acids with the amine group further acylated by another fatty acid; if this fatty acid is oleic acid the resulting molecule is N-oleoyl-phosphatidylethanolamine (NOPE). NOPE is a natural constituent of soy lecithin, and when any NAPE molecule is cleaved by the enzyme N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD) the lipid bound to the amine is released. In the case of NOPE, the lipid that is released is oleoylethanolamide (OEA).

NOPE can be produced endogenously when phosphatidylcholine (PC) donates an oleic acid molecule from the sn-1 position towards the amine group of phosphatidylethanolamine (PE), creating NOPE. When this occurs, the standard metabolism via NAPE-PLD can again produce OEA.


2Molecular Targets

2.1. PPARs

Oleoylethanolamide (OEA) is known to be a PPARα agonist, which accounts for its appetite-suppressing effects, since these effects are not seen in mice lacking this receptor and a reduction in food intake can be induced with synthetic PPARα agonists.[5] This reduction in food intake appears to reflect an increase in time between feedings rather than an decrease in food intake upon feeding in free-feeding rats based on their eating patterns. However in food-deprived rats OEA reduces food intake per meal as well as increases time between meals.[10]

OEA activates PPARα with an EC50 value of 120nM whereas its actions on PPARβ/δ were significantly weaker (1,100nM, or 1.1µM) and activity on PPARγ was undetectable up to concentrations of 50µM, suggesting relative selectivity for PPARα.[5] This activity on PPARα is also significantly more than the similarly-structured fatty acids oleic acid (EC50 of 10.3µM) and other acylethanlamides tested such as anandamide which had no significant effect.[5]

2.2. GPRs

The G-Protein Coupled Receptor (GPR) known as GPR119 was, up until recently, considered an orphan receptor (a receptor with no known endogenous ligand); however, it was found that OEA appears to be the endogenous agonist of GPR119[11][12] with an EC50 of around 2.3µM.[12] The orphan receptor GPR55 also binds OEA with an EC50 of around 4nM,[13] and is related in function to peripheral cannabinoid receptors (which do not contribute to the classical psychogenic activity attributed to cannabinoids).[14][15]

These receptors are also present in the intestines where they have roles in the secretion of the intestinal hormone Glucagon-Like Peptide-1 (GLP-1) and play a role in appetite suppression via the GPR119 receptor[11][12] and in regulating intestinal motility (unrelated to PPARα activity[16]).

Two GPR receptors, GPR55 and GPR 119, interact with OEA and may account for some of its effects in the body.


3Pharmacology

3.1. Absorption

Oleoylethanolamide (OEA) has been hypothesized[17] to have poor availability, since an enzyme that degrades it, fatty acid amide hydrolase (FAAH), is present in high levels in the intestinal tract and liver.[18][19]

Only 0.48% of the orally-administered dose was found to be intact in the intestines 90 minutes after ingestion of 10mg/kg in rats, but this still increased the basal concentration in intestinal tissue (0.354nM/g) 11-fold to 3.91+/-0.98nM/g and was as effective as 5mg/kg peripheral injections in suppressing food intake.[17] Combining oral oleate and ethanolamine separately did not replicate the effect of OEA even when controlled for the same oral dose, suggesting the metabolites of OEA did not affect feeding at this concentration[17] (oleate itself could suppress appetite, but it requires a significantly higher concentration in the intestines[20]).

Orally-ingested OEA appears to be extensively metabolized in the intestine, but despite this near-complete metabolism, orally-ingested OEA is still effective in modifying food intake in rats.


4Neurology

4.1. Adrenergic Neurotranmission

Peripheral injections of 5-20mg/kg oleoylethanolamide (OEA) into rats increased noradrenaline concentrations in the hypothalamus between 13-26% after one hour in a dose-dependent manner.[3]

4.2. Serotonergic Neurotransmission

Despite increasing noradrenaline and dopamine, peripheral injections of 5-20mg/kg OEA into rats failed to alter concentrations of serotonin or its metabolite (5-HIAA) in the hypothalamus.[3]

4.3. Dopaminergic Neurotransmission

Injections of 5-20mg/kg OEA into rats were able to increase hypothalamic dopamine concentrations in a dose-dependent manner between 116-140% whereas concentrations of the major metabolite of dopamine (DOPAC) were unaltered after one hour.[3] Injections of OEA directly into the brain of rats also increased dopamine levels in the nucleus accumbens.[21]

4.4. Miscellaneous Mechanisms

Oxytocin is a hormone involved in a variety of processes including suppressing appetite[22][23] and exerting antiobese effects,[23][24] and although atypical of hormones oxytocin appears to be able to induce its own synthesis and release.[25]

OEA has been shown to increase oxytocin levels in the brain in a manner dependent on PPARα activation[26] and oxytocin itself stimulates the production of OEA in adipocytes (following intracerebroventricular infusion and without stimulating serum OEA or cannabinoid metabolites[23]) and appears to also require the presence of PPARα.[23]

Due to a positive feedback mechanism between OEA and oxytocin, both agents are implicated in increasing levels of the other. Increases in central oxytocin appear to be able to be transported towards adipocytes and increases local OEA production

4.5. Appetite and Food Intake

The mechanism underlying the ability of OEA to suppress food intake is via PPARα activation in the intestines, as mice lacking PPARα do not experience the reduction of food intake from OEA (implicating that receptor) and damaging the vagus nerve below the diaphragm also ablated the effects (indicating that OEA is not acting centrally in suppressing food intake).[5] The small intestine is known to contain large amounts of the PPARα receptor[27][28] and since even intraperitoneal injections of OEA activate PPARα in this tissue[5] while injections directly into the brain do not work to suppress food intake (despite ultimately influencing the brain)[29] OEA's interaction with intestinal PPARα is thought to be the inital step in the signalling cascade.

The properties of OEA differ from the appetite-suppressing hormone cholecystokinin (CCK), which does not delay time to next meal in free-feeding rats like OEA does.[10] CCK is secreted from the intestines in response to a meal to cause satiety acutely.[30]

Oleoylethanolamide appears to work in the intestines, activating a receptor known as PPARα to ultimately influence the brain to reduce food intake. Injecting directly into the brain does not appear effective in reducing food intake despite ultimately influencing the brain.

Following an injection of 5mg/kg OEA into rats, the levels of appetite-stimulating peptides NPY and AgRP failed to be altered in either the fed or 24-hour fasted state relative to control injections, despite both peptides increasing greatly during the fasting period.[3]

The concentration of the anorectic (appetite-suppressing) peptide known as the Cocaine and Amphetamine Regulated Transcript (CART) has been affected by peripheral injections of OEA when measured in the paraventricular nucleus but not the arcuate nucleus, where two hours after the injection of OEA the reduction in CART induced by fasting (15-20%) was ablated.[3]

When looking at central (in the brain) peptides regulating food intake, it appears that OEA administration may preserve a decrease in appetite-suppressing peptides yet it does not necessarily blunt an increase in the appetite-promoting peptides seen during fasting.

The same injections of 5mg/kg OEA to rats caused time-dependent reductions in peptide YY (PYY, a hormone secreted from the gut[31]) in both the fasted and fed state.[3]

With respect to peripheral peptides regulating hunger, PYY (an appetite-stimulating hormone) appears to be reduced with injections of OEA in rats.

Injections of OEA at 5mg/kg to rats appeared to reduce spontaneous food intake over the course of the next four hours,[3] and acute suppression of food intake in rats is known to occur with peripheral injections of OEA in rats.[5][10] When comparing fed rats to fasted rats reintroduced to food, OEA administration seems more effective in the latter and there does not appear to be recompensation for this anorectic effect.[3][10]

Oral ingestion of OEA (10mg/kg) given to fasted rats 90 minutes prior to food reintroduction reduces food intake by 15.5% relative to control.[17]

Injections appear to be effective in reducing food intake in rats, and OEA has also been shown to be effective within 90 minutes of being given to rats orally.

4.6. Anxiety

Peripheral injections of OEA sufficient to cause food intake reduction do not appear to modify stress hormones or anxiety in rats.[29]

4.7. Depression

Mice who were given 1.5-6 mg/kg OEA started 7 days into a 28-day period of chronic unpredictable mild stress had improvements in signs of depression (behavior in an open field test and sucrose preference) to a degree similar to 6 mg/kg fluoxetine.[32] This was accompanied by a mitigated hormonal stress response and normalized brain-derived neurotrophic factor levels in the hippocampus and prefrontal cortex.[32]


5Obesity and Fat Mass

5.1. Adipokines

Injections of oleoylethanolamide (OEA) at 5mg/kg into rats in the fed state does not appear to have a significant influence on circulating adiponectin concentrations,[3] while injecting the same dose of OEA into rats that have been fasted appears to increase adiponectin after two hours but not six hours.[3] Adiponectin has been noted to be increased elsewhere with the same injected dose, albeit over six continual days. This 11.8% increase did not occur, however, when the β3-adrenergic agonist CL316243 was coadministered.[33]

Although coadministration of CL316243 and OEA is able to reduce leptin concentrations in rats (possibly associated with increases in energy expenditure and reductions in fat mass), neither agent in isolation affects leptin.[33]

Repeated doses over six days, but not single dosing, of injected OEA may increase adiponectin levels by 12% in rats.

5.2. Lipolysis

The β-adrenergic receptors are known to positively mediate body fat loss (mice lacking the receptors experience obesity[34]) and activation of the β3-adrenergic receptor encourages a reduction in food intake and fat loss in rodents,[35] in part via activating uncoupling proteins such as UCP1.[36][37]

OEA targets PPARα, and PPARα is known to have increased effects when the β3 receptor is activated[38] which partly mediates the effects of β3 on other lipolytic proteins such as PGC-1α and Uncoupling Protein 1 (UCP1) in brown adipose tissue.[39][40] In accordance with the hypotheses, coadministration of OEA (5mg/kg peripheral injection) and a β3 agonist appear to be additive in reducing food intake and synergistic in reducing fat mass in rats associated with an increase in energy expenditure (with no influence on locomotor activity).[33] At least in rats, the increase in PPARα and UCP1 (thought to reflect the increase in energy expenditure) occurred in both white and brown adipose tissue alongside improvements in mitochondrial biomarkers (Cox4i1, Cox4i2, Fgf21 and Prdm16).[33]

OEA appears to be able to enhance the thermogenic actions and mitochondrial effects of β3-adrenergic receptor activation in rats in both white and brown adipose tissues, at the same dose as that used to suppress appetite.

5.3. Weight

One study assessing the actions of a complex between NOPE (85mg) and EGCG from green tea catechins (50mg via 121mg green tea extract) taken twice daily alongside a mild caloric deficit for eight weeks in overweight adults noted that supplementation was associated with greater dietary adherence (94% of the group completing the trial relative to 74% in placebo).[1] Persons given the NOPE-EGCG complex reported less symptoms of binge eating and depressive symptoms and more meal-induced satiety, although overall weight loss during the trial did not differ between groups.[1]

A later study using the same formulation with modified dosages (120mg NOPE and 105mg EGCG) noted similar effects after four weeks although the benefit to compliance and mood was no longer apparent after eight weeks.[2]


6Interactions with Hormones

6.1. Ghrelin

Peripheral injections of oleoylethanolamide (OEA) administered to rats deprived of food for 24-hours did not influence ghrelin within two hours, but after six hours there was a significant reduction in this appetite-stimulating hormone by 40-50%;[3] OEA had no influence on the ghrelin concentrations of fed rats.[3]

6.2. Peptide YY

Injections of 5mg/kg OEA to rats appears to cause time-dependent reductions in peptide YY (PYY, a hormone secreted from the gut[31]) in both the fasted and fed state.[3]

With respect to peripheral peptides regulating hunger, PYY (an appetite-stimulating hormone) appears to be reduced with injections of OEA in rats.


7Peripheral Organ Systems

7.1. Pancreas

Oleoylethanolamide (OEA) is a known endogenous agonist of the fatty acid receptor GPR119,[11] and activation of this receptor in the pancreas or enteroendocrine cells of mouse intestines stimulates release of the hormone GLP-1.[41][42]

There are some pancreatic protective effects of OEA in the concentration range of 5-100µM (maximal at 60µM) in vitro, although these are not related to either GPR119 or PPARα activation.[43] Since inhibiting Fatty Acid Amide Hydrolase (FAAH, which is the enzyme that degrades OEA) removes the protective effects, these effects are thought to be due to oleate, which is a metabolite of OEA.[43]


8Interactions with Medical Conditions

8.1. Parkinson's Disease

In dopaminergic neurons from the substantia nigra in vitro, 0.5-15μM (0.16-4.8 μg/mL) oleoylethanolamide (OEA) added prior to the dopaminergic toxin 6-OHDA results in a bell curve of protective effects peaking in efficacy at 1μM.[44] It is thought to act via the PPARα receptor expressed in these neurons[44][45] as other PPARα agonists (fibrates) have been noted to be protective.[46] This mechanism of action, however, has not been directly confirmed, and antagonism of TRPV1 as OEA's mechanism of action is also plausible since these receptors are expressed in the same neurons.[47]

Scientific Support & Reference Citations

References

  1. Rondanelli M1, et al. Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial. Br J Nutr. (2009)
  2. Mangine GT1, et al. The effect of a dietary supplement (N-oleyl-phosphatidyl-ethanolamine and epigallocatechin gallate) on dietary compliance and body fat loss in adults who are overweight: a double-blind, randomized control trial. Lipids Health Dis. (2012)
  3. Serrano A, et al. Oleoylethanolamide: effects on hypothalamic transmitters and gut peptides regulating food intake. Neuropharmacology. (2011)
  4. Petrosino S, Di Marzo V. Anandamide and Other Acylethanolamides. Handbook of Neurochemistry and Molecular Neurobiology. (2010)
  5. Fu J, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. (2003)
  6. Thabuis C, et al. Biological functions and metabolism of oleoylethanolamide. Lipids. (2008)
  7. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci. (1997)
  8. Di Marzo V, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. (1994)
  9. Cravatt BF, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. (1996)
  10. Gaetani S, Oveisi F, Piomelli D. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology. (2003)
  11. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes. (2009)
  12. Overton HA, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. (2006)
  13. Ryberg E, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. (2007)
  14. Begg M, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther. (2005)
  15. Petitet F, Donlan M, Michel A. GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des. (2006)
  16. Cluny NL, et al. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil. (2009)
  17. Nielsen MJ, et al. Food intake is inhibited by oral oleoylethanolamide. J Lip Res. (2004)
  18. Schmid PC, Zuzarte-Augustin ML, Schmid HH. Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem. (1985)
  19. Katayama K, et al. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta. (1997)
  20. Cox JE, et al. Suppression of food intake, body weight, and body fat by jejunal fatty acid infusions. Am J Physiol Regul Integr Comp Physiol. (2000)
  21. Murillo-Rodríguez E, et al. Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats. PLoS One. (2011)
  22. Arletti R1, Benelli A, Bertolini A. Influence of oxytocin on feeding behavior in the rat. Peptides. (1989)
  23. Deblon N1, et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One. (2011)
  24. Zhang G1, et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron. (2011)
  25. Gimpl G1, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. (2001)
  26. Gaetani S, et al. The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin. J Neurosci. (2010)
  27. Martin G, et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem. (1997)
  28. Escher P, et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology. (2001)
  29. Rodríguez de Fonseca F, et al. An anorexic lipid mediator regulated by feeding. Nature. (2001)
  30. Little TJ, Horowitz M, Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes Rev. (2005)
  31. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. (2003)
  32. Jin P, et al. Antidepressant-like effects of oleoylethanolamide in a mouse model of chronic unpredictable mild stress. Pharmacol Biochem Behav. (2015)
  33. Suárez J, et al. Oleoylethanolamide enhances β-adrenergic-mediated thermogenesis and white-to-brown adipocyte phenotype in epididymal white adipose tissue in rat. Dis Model Mech. (2014)
  34. Bachman ES, et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science. (2002)
  35. White CL, et al. Effect of a beta-3 agonist on food intake in two strains of rats that differ in susceptibility to obesity. Physiol Behav. (2004)
  36. Dallner OS, et al. Beta3-adrenergic receptors stimulate glucose uptake in brown adipocytes by two mechanisms independently of glucose transporter 4 translocation. Endocrinology. (2006)
  37. Klein J, et al. Insulin and the beta3-adrenoceptor differentially regulate uncoupling protein-1 expression. Mol Endocrinol. (2000)
  38. Li P, et al. Metabolic and cellular plasticity in white adipose tissue II: role of peroxisome proliferator-activated receptor-alpha. Am J Physiol Endocrinol Metab. (2005)
  39. Villarroya F, Iglesias R, Giralt M. PPARs in the Control of Uncoupling Proteins Gene Expression. PPAR Res. (2007)
  40. Hondares E, et al. Peroxisome proliferator-activated receptor α (PPARα) induces PPARγ coactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16. J Biol Chem. (2011)
  41. Lan H, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol. (2012)
  42. Moran BM, et al. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice. Biol Chem. (2013)
  43. Stone VM, et al. The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119. Br J Pharmacol. (2012)
  44. Galan-Rodriguez B, et al. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology. (2009)
  45. Moreno S, Farioli-Vecchioli S, Cerù MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. (2004)
  46. Deplanque D, et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. (2003)
  47. Mezey E, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A. (2000)

(Common misspellings for Oleoylethanolamide include oleoilethanolamide, oloylethanolamide, OAE, EOA oleicethanolamide)